Hengsai Biotechnology
恒赛生物
Hengsai Biotechnology
Biotech/Healthcare
Founded in 2018, Hongsai Biotech has an R&D center in Shanghai and is a high-tech company focused on cancer immunotherapy. It primarily develops and commercializes next-generation personalized dendritic cell cancer therapeutic vaccines (DC vaccines), with the aim of developing internationally…
Latest round: Series B (2026)
Source: ChinaBulls — chinabulls.com
Last updated 2026-08-01
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.